Gsa Capital Partners LLP Curis Inc Transaction History

Gsa Capital Partners LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.57 - $0.99 $110,670 - $192,217	194,159 Added 523.68%	231,235 $191,000
Q1 2023 May 12, 2023	BUY	$0.51 - $0.78 $18,908 - $28,919	37,076 New	37,076 $22,000
Q2 2022 Aug 09, 2022	SELL	$0.71 - $2.43 $23,654 - $80,957	-33,316 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$2.31 - $5.13 $26,953 - $59,856	11,668 Added 53.9%	33,316 $79,000
Q4 2021 Feb 14, 2022	BUY	$4.45 - $8.09 $96,333 - $175,132	21,648 New	21,648 $103,000
Q3 2021 Nov 12, 2021	SELL	$6.94 - $8.85 $429,537 - $547,753	-61,893 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$7.45 - $16.27 $461,102 - $1.01 Million	61,893 New	61,893 $499,000
Q4 2020 Feb 03, 2021	SELL	$1.08 - $8.2 $328,331 - $2.49 Million	-304,011 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$0.95 - $1.42 $288,810 - $431,695	304,011 New	304,011 $356,000
Q3 2018 Nov 13, 2018	SELL	$1.38 - $1.94 $471,990 - $663,522	-342,022 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$1.73 - $3.35 $591,698 - $1.15 Million	342,022 New	342,022 $592,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $409M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.